Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01100060 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT01100060: Completed Phase 1 study, sponsored by Pfizer.

NCT01100060 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01100060, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

Estimate the relative bioavailability of co-administered azithromycin microsphere (2000 mg) and the chloroquine (620 mg CQ base) test formulation compared to co-administered immediate release individual tablets of azithromycin (2000 mg) and chloroquine (600 mg CQ base) in healthy adult subjects.

Interventions

  • DRUG azithromycin (AZ) microsphere
  • DRUG test chloroquine (CQ) formulation
  • DRUG azithromycin (AZ)
  • DRUG chloroquine (CQ)

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2010-04
Est. Completion 2010-06
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT01100060 record still lists

NCT01100060 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 4 interventions - of which azithromycin (AZ) microsphere is the first listed.

NCT01100060 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01100060 about?

NCT01100060 is a clinical study titled "A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects". Estimate the relative bioavailability of co-administered azithromycin microsphere (2000 mg) and the chloroquine (620 mg CQ base) test formulation compared to co-administered immediate release individual tablets of azithromycin (2000 mg) and chloroquine (600 mg CQ base) in healthy adult subjects.

What is the current status of trial NCT01100060?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2010-04. Estimated completion is 2010-06.

What interventions are being tested in trial NCT01100060?

The interventions under investigation include: azithromycin (AZ) microsphere (DRUG), test chloroquine (CQ) formulation (DRUG), azithromycin (AZ) (DRUG), chloroquine (CQ) (DRUG).

Who is sponsoring clinical trial NCT01100060?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01100060's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01100060, the US trial registry maintained by the National Library of Medicine. NCT01100060 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.